BRCA1 and implications for response to chemotherapy in ovarian cancer

Gynecologic Oncology

Volumn 113, Issue 1, 2009, Pages 134-142

  Quinn, Jennifer E ^a   Carser, Judith E ^a   James, Colin R ^a   Kennedy, Richard D ^a   Harkin, D Paul ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

BRCA1; Chemotherapy; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; MITOMYCIN C; NOCODAZOLE; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; TUMOR MARKER;

BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL DAMAGE; DATA ANALYSIS; DNA REPAIR; DRUG CYTOTOXICITY; DRUG RESPONSE; DRUG SENSITIVITY; FAMILIAL CANCER; FEMALE; GENE CONTROL; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; HUMAN; MEDLINE; MICROTUBULE; NONHUMAN; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

BRCA1 PROTEIN; FEMALE; GENES, BRCA1; GERM-LINE MUTATION; HUMANS; OVARIAN NEOPLASMS;

EID: 62549147782     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.12.015     Document Type: Review

References (110)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
2. Collaborative Group on Epidemiological Studies of Ovarian C. Beral V., Doll R., Hermon C., Peto R., and Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371 (2008) 303-314
3. Narod S.A., Dube M.P., Klijn J., Lubinski J., Lynch H.T., Ghadirian P., et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J. Natl. Cancer Inst. 94 (2002) 1773-1779
4. Brown M.A., Lo L.J., Catteau A., Xu C.F., Lindeman G.J., Hodgson S., et al. Germline BRCA1 promoter deletions in UK and Australian familial breast cancer patients: identification of a novel deletion consistent with BRCA1:psiBRCA1 recombination. Hum. Mutat. 19 (2002) 435-442
5. Boyd J. BRCA: the breast, ovarian, and other cancer genes. Gynecol. Oncol. 80 (2001) 337-340
6. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334 (1996) 1-6
7. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med. 351 (2004) 2519-2529
8. Schuijer M., and Berns E.M. TP53 and ovarian cancer. Hum. Mutat. 21 (2003) 285-291
9. Herod J.J., Eliopoulos A.G., Warwick J., Niedobitek G., Young L.S., and Kerr D.J. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res. 56 (1996) 2178-2184
10. Perego P., Giarola M., Righetti S.C., Supino R., Caserini C., Delia D., et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56 (1996) 556-562
11. Jones N.A., Turner J., McIlwrath A.J., Brown R., and Dive C. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol. Pharmacol. 53 (1998) 819-826
12. Hall J., Paul J., and Brown R. Critical evaluation of p53 as a prognostic marker in ovarian cancer. Expert Rev. Mol. Med. 6 (2004) 1-20
13. Baekelandt M., Holm R., Nesland J.M., Trope C.G., and Kristensen G.B. Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. J. Clin. Oncol. 18 (2000) 3775-3781
14. Baekelandt M., Kristensen G.B., Nesland J.M., Trope C.G., and Holm R. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. J. Clin. Oncol. 17 (1999) 2061
15. Aebi S., Kurdi-Haidar B., Gordon R., Cenni B., Zheng H., Fink D., et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 56 (1996) 3087-3090
16. Fink D., Aebi S., and Howell S.B. The role of DNA mismatch repair in drug resistance. Clin. Cancer Res. 4 (1998) 1-6
17. Plumb J.A., Strathdee G., Sludden J., Kaye S.B., and Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 60 (2000) 6039-6044
18. Helleman J., van Staveren I.L., Dinjens W.N., van Kuijk P.F., Ritstier K., Ewing P.C., et al. Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer 6 (2006) 201
19. Mesquita B., Veiga I., Pereira D., Tavares A., Pinto I.M., Pinto C., et al. No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin. BMC Cancer 5 (2005) 101
20. Gifford G., Paul J., Vasey P.A., Kaye S.B., and Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin. Cancer Res. 10 (2004) 4420-4426
21. Ferry K.V., Hamilton T.C., and Johnson S.W. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem. Pharmacol. 60 (2000) 1305-1313
22. Lin K., Ye D., and Xie X. Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer. Int. J. Gynecol. Cancer 18 (2008) 1007-1012
23. Smith S., Su D., Rigault de la Longrais I.A., Schwartz P., Puopolo M., Rutherford T.J., et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J. Clin. Oncol. 25 (2007) 5172-5179
24. Giannakakou P., Sackett D.L., Kang Y.K., Zhan Z., Buters J.T., Fojo T., et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 272 (1997) 17118-17125
25. Mozzetti S., Ferlini C., Concolino P., Filippetti F., Raspaglio G., Prislei S., et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin. Cancer Res. 11 (2005) 298-305
26. Penson R.T., Oliva E., Skates S.J., Glyptis T., Fuller Jr. A.F., Goodman A., et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol. Oncol. 93 (2004) 98-106
27. Ferlini C., Raspaglio G., Mozzetti S., Distefano M., Filippetti F., Martinelli E., et al. Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol. Pharmacol. 64 (2003) 51-58
28. Zaffaroni N., Pennati M., Colella G., Perego P., Supino R., Gatti L., et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol. Life Sci. 59 (2002) 1406-1412
29. Cassinelli G., Supino R., Perego P., Polizzi D., Lanzi C., Pratesi G., et al. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int. J. Cancer 92 (2001) 738-747
30. Pal T., Permuth-Wey J., Betts J.A., Krischer J.P., Fiorica J., Arango H., et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104 (2005) 2807-2816
31. Chen S., Iversen E.S., Friebel T., Finkelstein D., Weber B.L., Eisen A., et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J. Clin. Oncol. 24 (2006) 863-871
32. King M.C., Marks J.H., and Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 (2003) 643-646
33. Rubin S.C., Benjamin I., Behbakht K., Takahashi H., Morgan M.A., LiVolsi V.A., et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N. Engl. J. Med. 335 (1996) 1413-1416
34. Boyd J., Sonoda Y., Federici M.G., Bogomolniy F., Rhei E., Maresco D.L., et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. Jama 283 (2000) 2260-2265
35. Johannsson O.T., Ranstam J., Borg A., and Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J. Clin. Oncol. 16 (1998) 397-404
36. Aida H., Takakuwa K., Nagata H., Tsuneki I., Takano M., Tsuji S., et al. Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin. Cancer Res. 4 (1998) 235-240
37. Pharoah P.D., Easton D.F., Stockton D.L., Gayther S., and Ponder B.A. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res. 59 (1999) 868-871
38. Ramus S.J., Bobrow L.G., Pharoah P.D., Finnigan D.S., Fishman A., Altaras M., et al. Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. Genes Chromosomes Cancer 25 (1999) 91-96
39. Lakhani S.R., Manek S., Penault-Llorca F., Flanagan A., Arnout L., Merrett S., et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin. Cancer Res. 10 (2004) 2473-2481
40. Rubin S.C., Blackwood M.A., Bandera C., Behbakht K., Benjamin I., Rebbeck T.R., et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am. J. Obstet. Gynecol. 178 (1998) 670-677
41. Majdak E.J., De Bock G.H., Brozek I., Perkowska M., Ochman K., Debniak J., et al. Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report. Eur. J. Cancer 41 (2005) 143-150
42. Jazaeri A.A., Yee C.J., Sotiriou C., Brantley K.R., Boyd J., and Liu E.T. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J. Natl. Cancer Inst. 94 (2002) 990-1000
43. McCoy M.L., Mueller C.R., and Roskelley C.D. The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer. Reprod. Biol. Endocrinol. 1 (2003) 72
44. Russell P.A., Pharoah P.D., De Foy K., Ramus S.J., Symmonds I., Wilson A., et al. Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers. Int. J. Cancer 87 (2000) 317-321
45. Zheng W., Luo F., Lu J.J., Baltayan A., Press M.F., Zhang Z.F., et al. Reduction of BRCA1 expression in sporadic ovarian cancer. Gynecol. Oncol. 76 (2000) 294-300
46. Thrall M., Gallion H.H., Kryscio R., Kapali M., Armstrong D.K., and DeLoia J.A. BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int. J. Gynecol. Cancer 16 Suppl 1 (2006) 166-171
47. Weberpals J.I., Clark-Knowles K.V., and Vanderhyden B.C. Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. J. Clin. Oncol. 26 (2008) 3259-3267
48. Baldwin R.L., Nemeth E., Tran H., Shvartsman H., Cass I., Narod S., et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 60 (2000) 5329-5333
49. Geisler J.P., Hatterman-Zogg M.A., Rathe J.A., and Buller R.E. Frequency of BRCA1 dysfunction in ovarian cancer. J. Natl. Cancer Inst. 94 (2002) 61-67
50. Wagner A.H., Schwabe O., and Hecker M. Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br. J. Pharmacol. 136 (2002) 143-149
51. Hedenfalk I., Duggan D., Chen Y., Radmacher M., Bittner M., Simon R., et al. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344 (2001) 539-548
52. James C.R., Quinn J.E., Mullan P.B., Johnston P.G., and Harkin D.P. BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist 12 (2007) 142-150
53. Foulkes W.D. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam. Cancer 5 (2006) 135-142
54. Murray M.M., Mullan P.B., and Harkin D.P. Role played by BRCA1 in transcriptional regulation in response to therapy. Biochem. Soc. Trans. 35 (2007) 1342-1346
55. Mullan P.B., Quinn J.E., and Harkin D.P. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 25 (2006) 5854-5863
56. McHugh P.J., Spanswick V.J., and Hartley J.A. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol. 2 (2001) 483-490
57. Tutt A., and Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol. Med. 8 (2002) 571-576
58. Gudmundsdottir K., and Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25 (2006) 5864-5874
59. Martin L.P., Hamilton T.C., and Schilder R.J. Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res. 14 (2008) 1291-1295
60. de Laat W.L., Jaspers N.G., and Hoeijmakers J.H. Molecular mechanism of nucleotide excision repair. Genes Dev. 13 (1999) 768-785
61. Gowen L.C., Avrutskaya A.V., Latour A.M., Koller B.H., and Leadon S.A. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 281 (1998) 1009-1012
62. Abbott D.W., Thompson M.E., Robinson-Benion C., Tomlinson G., Jensen R.A., and Holt J.T. BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J. Biol. Chem. 274 (1999) 18808-18812
63. Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., and Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev. 14 (2000) 927-939
64. Hartman A.R., and Ford J.M. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat. Genet. 32 (2002) 180-184
65. Yun J., Zhong Q., Kwak J.Y., and Lee W.H. Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest. Oncogene 24 (2005) 4009-4016
66. Bhattacharyya A., Ear U.S., Koller B.H., Weichselbaum R.R., and Bishop D.K. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 275 (2000) 23899-23903
67. Zhou C., Huang P., and Liu J. The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells. Biochem. Biophys. Res. Commun. 336 (2005) 952-960
68. Xing D., and Orsulic S. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res. 66 (2006) 8949-8953
69. D'Andrea A.D. The Fanconi anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle 2 (2003) 290-292
70. Kennedy R.D., and D'Andrea A.D. The Fanconi anemia/BRCA pathway: new faces in the crowd. Genes Dev. 19 (2005) 2925-2940
71. Kennedy R.D., and D'Andrea A.D. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J. Clin. Oncol. 24 (2006) 3799-3808
72. Chirnomas D., Taniguchi T., de la Vega M., Vaidya A.P., Vasserman M., Hartman A.R., et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol. Cancer Ther. 5 (2006) 952-961
73. McGrogan B.T., Gilmartin B., Carney D.N., and McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 1785 (2008) 96-132
74. Quinn J.E., James C.R., Stewart G.E., Mulligan J.M., White P., Chang G.K., et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin. Cancer Res. 13 (2007) 7413-7420
75. Quinn J.E., Kennedy R.D., Mullan P.B., Gilmore P.M., Carty M., Johnston P.G., et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 63 (2003) 6221-6228
76. Byrski T., Gronwald J., Huzarski T., Grzybowska E., Budryk M., Stawicka M., et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res. Treat 108 (2008) 289-296
77. Mullan P.B., Gorski J.J., and Harkin D.P. BRCA1-A good predictive marker of drug sensitivity in breast cancer treatment?. Biochim. Biophys. Acta 1766 (2006) 205-216
78. Hsu L.C., Doan T.P., and White R.L. Identification of a gamma-tubulin-binding domain in BRCA1. Cancer Res. 61 (2001) 7713-7718
79. Starita L.M., Machida Y., Sankaran S., Elias J.E., Griffin K., Schlegel B.P., et al. BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number. Mol. Cell. Biol. 24 (2004) 8457-8466
80. Deng C.X., and Wang R.H. Roles of BRCA1 in DNA damage repair: a link between development and cancer. Hum. Mol. Genet. 12 Spec No 1 (2003) R113-123
81. Wang C., Horiuchi A., Imai T., Ohira S., Itoh K., Nikaido T., et al. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J. Pathol. 202 (2004) 215-223
82. Chabalier C., Lamare C., Racca C., Privat M., Valette A., and Larminat F. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 5 (2006) 1001-1007
83. Wang X., Jin D.Y., Ng R.W., Feng H., Wong Y.C., Cheung A.L., et al. Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells. Cancer Res. 62 (2002) 1662-1668
84. Fu Y., Ye D., Chen H., Lu W., Ye F., and Xie X. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30. Gynecol. Oncol. 105 (2007) 66-73
85. Harkin D.P., Bean J.M., Miklos D., Song Y.H., Truong V.B., Englert C., et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 97 (1999) 575-586
86. Thangaraju M., Kaufmann S.H., and Couch F.J. BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J. Biol. Chem. 275 (2000) 33487-33496
87. Gilmore P.M., McCabe N., Quinn J.E., Kennedy R.D., Gorski J.J., Andrews H.N., et al. BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3. Cancer Res. 64 (2004) 4148-4154
88. Husain A., He G., Venkatraman E.S., and Spriggs D.R. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res. 58 (1998) 1120-1123
89. Lafarge S., Sylvain V., Ferrara M., and Bignon Y.J. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 20 (2001) 6597-6606
90. Tassone P., Tagliaferri P., Perricelli A., Blotta S., Quaresima B., Martelli M.L., et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br. J. Cancer 88 (2003) 1285-1291
91. Fedier A., Steiner R.A., Schwarz V.A., Lenherr L., Haller U., and Fink D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int. J. Oncol. 22 (2003) 1169-1173
92. Sgagias M.K., Wagner K.U., Hamik B., Stoeger S., Spieker R., Huber L.J., et al. Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS. Cell Cycle 3 (2004) 1451-1456
93. DelloRusso C., Welcsh P.L., Wang W., Garcia R.L., King M.C., and Swisher E.M. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. Mol. Cancer Res. 5 (2007) 35-45
94. Zhou C., Smith J.L., and Liu J. Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 22 (2003) 2396-2404
95. Sylvain V., Lafarge S., and Bignon Y.J. Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int. J. Oncol. 20 (2002) 845-853
96. Clark-Knowles K.V., Garson K., Jonkers J., and Vanderhyden B.C. Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp. Cell Res. 313 (2007) 133-145
97. Bartz S.R., Zhang Z., Burchard J., Imakura M., Martin M., Palmieri A., et al. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol. Cell. Biol. 26 (2006) 9377-9386
98. Swisher E.M., Sakai W., Karlan B.Y., Wurz K., Urban N., and Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68 (2008) 2581-2586
99. Cass I., Baldwin R.L., Varkey T., Moslehi R., Narod S.A., and Karlan B.Y. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97 (2003) 2187-2195
100. Majdak E.J., Debniak J., Milczek T., Cornelisse C.J., Devilee P., Emerich J., et al. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 104 (2005) 1004-1012
101. Brozek I., Ochman K., Debniak J., Morzuch L., Ratajska M., Stepnowska M., et al. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland. Gynecol. Oncol. 108 (2008) 433-437
102. Chetrit A., Hirsh-Yechezkel G., Ben-David Y., Lubin F., Friedman E., and Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J. Clin. Oncol. 26 (2008) 20-25
103. Tan D.S., Rothermundt C., Thomas K., Bancroft E., Eeles R., Shanley S., et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J. Clin. Oncol. 26 (2008) 5530-5536
104. Teodoridis J.M., Hall J., Marsh S., Kannall H.D., Smyth C., Curto J., et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res. 65 (2005) 8961-8967
105. Mullan P.B., Quinn J.E., Gilmore P.M., McWilliams S., Andrews H., Gervin C., et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 20 (2001) 6123-6131
106. Tassone P., Blotta S., Palmieri C., Masciari S., Quaresima B., Montagna M., et al. Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents. Int. J. Oncol. 26 (2005) 1257-1263
107. Kurebayashi J., Yamamoto Y., Kurosumi M., Okubo S., Nomura T., Tanaka K., et al. Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes. Anticancer Res. 26 (2006) 695-701
108. Martin L., and Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J. Clin. Oncol. 25 (2007) 2894-2901
109. Kauff N.D. Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?. J. Clin. Oncol. 26 (2008) 9-10
110. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921